NT-IGFBP-4全自动化学发光免疫分析方法的建立及其在心力衰竭中的临床相关性
本研究开发了首个针对NT-IGFBP-4的全自动化学发光免疫分析方法(CLIA),并进行了全面的分析性能验证,包括空白限、检测限、定量限、线性、特异性、精密度、样本类型兼容性和稳定性。同时在健康人群中建立了参考区间并分析性别、年龄、BMI和肾功能的影响,探讨了NT-IGFBP-4在心血管疾病患者中的分布。结果显示该方法特异性高、灵敏度好(LoQ=1.0 ng/mL)、线性范围宽(1.0-1,000.0 ng/mL)、精密度强(CV≤3.0%),NT-IGFBP-4在心血管疾病尤其心力衰竭中显著升高,与NYHA分级和LVEF(%)相关。
要点
- NT-IGFBP-4全自动CLIA方法分析性能良好,LoQ=1.0 ng/mL,线性范围1.0-1,000.0 ng/mL,CV≤3.0%。
- NT-IGFBP-4参考区间受性别、年龄和肾功能影响,与BMI无关。
- NT-IGFBP-4在心力衰竭中显著升高,与NYHA分级和LVEF(%)相关,水平越高心功能越差。
核心结论
- 新型全自动NT-IGFBP-4化学发光免疫分析方法具有高特异性、高灵敏度和高精密度,其分析性能验证和疾病关联发现有助于提升其在心血管疾病尤其是心力衰竭中的诊断和预后潜力。
研究设计与样本
- 采用片段特异性单克隆抗体开发免疫分析方法,进行全面分析性能验证,并在健康人群中建立参考区间及分析性别、年龄、BMI和肾功能的影响,同时探索NT-IGFBP-4在心血管疾病患者中的分布。
主要发现
- 该方法对NT-IGFBP-4具有高特异性,定量限(LoQ)为1.0 ng/mL,线性范围为1.0-1,000.0 ng/mL,精密度CV≤3.0%。
- 该方法不受常见内源性物质干扰,兼容多种样本类型,在不同储存条件下保持稳定。
- 参考区间在性别和年龄间略有差异,NT-IGFBP-4水平与BMI无关但受肾功能影响。
- NT-IGFBP-4在心血管疾病中显著升高,尤其在心力衰竭中,与NYHA分级和LVEF(%)相关,水平越高提示心功能越差。
关键数值与推荐
- 定量限(LoQ)=1.0 ng/mL。
- 线性范围1.0-1,000.0 ng/mL。
- 精密度CV≤3.0%。
临床怎么用
- 该全自动CLIA方法可用于定量检测IGFBP-4片段,分析性能验证充分,适用于心血管疾病尤其是心力衰竭的临床研究和潜在诊断评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Insulin-like growth factor binding protein-4 (IGFBP-4) fragments are reported as emerging biomarkers for cardiovascular disease (CVD) risk assessment. To ensure data reliability and improve clinical application, the first automatic chemiluminescent immunoassay (CLIA) for NT-IGFBP-4 was developed and its distribution across CVDs was evaluated in this study. METHODS: Fragment-specific monoclonal antibodies were used to develop immunoassay, followed by comprehensive analytical validation, including limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), linearity, specificity, precision, sample type compatibility, and stability. Reference intervals for NT-IGFBP-4 were established in healthy individuals, with variations analyzed based on gender, age, body mass index (BMI), and renal function. Additionally, NT-IGFBP-4 distribution was explored in CVD patients. RESULTS: The newly developed chemiluminescence assay demonstrated high specificity for NT-IGFBP-4, with excellent sensitivity (LoQ=1.0 ng/mL), broad linearity (1.0-1,000.0 ng/mL), and strong precision (CV≤3.0 %). It showed no interference from common endogenous substances, maintained compatible with various sample types, and remained stable under different storage conditions. Reference intervals showed slight variations by gender and age, with levels being independent of BMI but influenced by renal function. NT-IGFBP-4 levels were significantly elevated in CVDs, especially in heart failure, correlating with NYHA classification and LVEF (%), with higher levels indicating worse cardiac function. CONCLUSIONS: The new automatic NT-IGFBP-4 (CLIA) assay offers a highly specific, sensitive and precise method for quantifying IGFBP-4 fragments. Its validated performance and disease association findings would enhance its diagnostic and prognostic potential in CVD research, particularly in heart failure.
引用
- Cao S, Wang J, Li L, et al. An automatic chemiluminescence immunoassay for a novel biomarker NT-IGFBP-4: analytical performance and clinical relevance in heart failure. Clin Chem Lab Med. 2025. PMID: 40842315. doi:10.1515/cclm-2025-0378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。